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Abstract 
Purpose: To compare the prevalence and type of potentially inappropriate medications (PIMs) and 
potential prescribing omissions (PPOs) on admission and discharge of patients, and to determine the 
associated predictors.  
Methods: This was a prospective observational study conducted in the multidisciplinary medical and 
surgical units of Hospital Tengku Ampuan Afzan (HTAA), Malaysia. The medications of patients who 
had been admitted to the hospital from community-dwelling settings were reviewed to identify 
PIMs/PPOs using version 2 of STOPP/START criteria. A logistic regression model was applied to detect 
the risk factors associated with PIM or PPO at discharge.  
Results: Among the 300 patients involved in the study, the prevalence of PIMs was 27 % upon 
admission, which decreased to 22.3 % at discharge (p = 0.014) with PIMs pertaining to increasing the 
risk of physical falls in elderly people being the most common for pre- and post-hospitalization. The 
prevalence of PPOs was 47.6 % upon admission, which increased to 48 % at discharge (p = 0.99), with 
the omission of musculoskeletal medications being the most common PPOs at admission and 
discharge. Having a PIM at discharge was associated with the number of discharge medications and 
the history of falls, whereas having a high comorbidity index score or history of falls was associated with 
having a PPO at discharge.  
Conclusion: Hospitalization significantly reduces the prevalence of PIMs, but not PPOs or 
polypharmacy, among elderly patients. The number of discharge medications and the history of falls are 
predictors of discharge PIM, whilst high comorbidities and the history of falls were the predictors of 
discharge PPO. Improving the knowledge of hospital practitioners regarding geriatric pharmacotherapy 
is required to optimize prescribing in elderly patients during hospitalization. 
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Potentially inappropriate prescribing (PIP) occurs 
when there is prescribing of a potentially 
inappropriate medication (PIM), where the risks 
associated with the medication outweigh the 
expected benefits, or when there is a potential 
prescribing omission (PPO), where a specific 
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medication is indicated but not yet prescribed 
[1,2]. Several studies have demonstrated the 
association between PIP and adverse drug 
reactions (ADRs) [3], increase in hospitalizations 
[4,5], decrease in patients’ adherence [6], and 
excess costs [7,8]. PIP is highly common in older 
adults[9]; and because of physiological and 
pathological changes occurring with advancing 
age, the negative outcomes of PIPs in elderly 
patients are of great concern [1].  
 
Inappropriate prescribing can be detected by 
either explicit or implicit criteria. Implicit criteria 
are judgment-based tools, whereas explicit 
criteria are criterion-based ones. Explicit criteria 
are developed from literature reviews and expert 
opinions, and are then endorsed using 
consensus techniques. Several explicit criteria 
have been formulated to identify PIPs in elderly 
patients. Among the most widely-used tools are 
the screening tool of older persons’ prescriptions 
(STOPP), and the screening tool to alert doctors 
to right treatment (START). The STOPP/START 
criteria were first introduced in 2008 [10], and 
were then updated and validated in 2014.[11]. 
The STOPP list comprises 80 criteria for 
identifying PIMs that should be avoided, either in 
all elderly adults or when there is drug-disease or 
drug-drug interaction. The START list contains 
34 criteria that address the common PPOs.  
 
Studies comparing different explicit criteria have 
concluded that the STOPP criteria are more 
sensitive than other available explicit criteria in 
detecting PIMs that are associated with ADRs 
[3,12,13]. Additionally, a systematic review of 
randomized controlled trials deduced that the use 
of the STOPP criteria reduces falls, duration of 
hospitalization, and treatment costs [2]. The use 
of the STOPP/START criteria has been 
expanding since their first release [2], and the 
criteria showed a good inter-rater reliability with 
physicians and pharmacists [14,15]. The 
European Union Geriatric Medicine Society 
(EUGMS) has announced its support for the 
STOPP/START criteria [16].  
 
The prevalence of PIP among elderly patients 
varies significantly, depending on the study 
design, tools used, and the targeted population. 
A multi-centre study conducted on hospitalized 
elderly patients in six European countries found a 
prevalence ranging from 34.7 to 77.3 % for PIMs, 
and from 51.3 to 72.7 % for PPOs, according to 
the STOPP/START criteria [17]. A comparable 
prevalence rate of 51 and 74 % for PIMs and 
PPOs, respectively was reported by an 
Australian hospital [18]. 
 
Hospital admissions seem to offer a chance for 
healthcare professionals (HCPs) to 
comprehensively review the medications of 
patients, optimize the prescribing and, therefore, 
reduce pre-admission PIMs and PPOs. However, 
minimizing PIPs in acute care settings is 
challenging. This may be due to lack of time, 
multiple interventions in the same patients by 
different specialists with difficulty of full 
coordination, and limited number of medications 
in hospital formularies[9]. Studies that compared 
the prevalence rate of PIPs pre- and post-
hospitalization found that the results were 
incompatible. These studies reported a decrease 
[19,20], increase [21], or insignificant change 
[22,23] in PIMs after hospitalization. As far as is 
known, there is no published study available that 
has assessed the impact of hospitalization on 
PIPs among elderly patients in Malaysia. Hence, 
this study was designed and conducted for the 
situation in the Malaysia as due to differences in 
the healthcare systems, available medications, 
and prescribing patterns between countries, it 
cannot be assumed that the prevalence and 
types of PIPs in all countries are identical.  
 
The main objectives of this study were:  to 
assess the impact of hospitalization on PIPs in 
community-dwelling elderly patients by 
comparing the prevalence and type of PIMs and 
PPOs pre- and post-hospitalization as identified 
by version 2 of the STOPP/START criteria; and 
to identify the factors associated with having a 




Study design and setting 
 
This study was a prospective observational study 
that took place in the multidisciplinary medical 
and surgical units of Hospital Tengku Ampuan 
Afzan (HTAA), Kuantan, Pahang, Malaysia from 
April to October 2016. HTAA is a tertiary hospital, 
with a capacity for 794 beds. Each involved unit 
consisted of 4 wards; 2 for men and 2 for 
women, with a total of 326 beds in the two units. 
The study was conducted in accordance with the 
guidelines of Declaration of Helsinki [24]. Ethical 
approval was obtained from Medical Research 
and Ethics Committee, Ministry of Health 
Malaysia (no. NMRR-15-718-25235), and from 
the Clinical Research Center (CRC) of the 
hospital. Informed consent was obtained from all 




Five hundred and seventeen consecutive 
community-dwelling inpatients were screened for  
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                 Figure 1: Flowchart of the patient recruitment process 
 
eligibility (Figure 1). Patients above 65 years who 
were admitted to the hospital for any medical or 
surgical reason, and who were on at least one 
medication for a minimum of three months prior 
to their hospitalization, were screened. Patients 
were excluded if they were living in long-term 
care facilities, e.g. nursing homes, could not 
speak or were unable to communicate in English 
or Malay, or if their pre-admission medications 
were not clearly stated in their records. Patients 
who died during hospitalization were also 
excluded. Patients who had multiple admissions 
during the study period were included during 
their first admission only. Eligible patients were 
identified daily from the admission records of 




Two trained pharmacists extracted the 
information from the patients’ records. This was 
followed by face-to-face interviews. The patients 
were approached individually and were given a 
verbal explanation about the study together with 
an information sheet written in Malay or English. 
The patients were monitored until their 
discharge. However, the pharmacists did not 
interfere with the treatment of the patients. 
 
The data extraction form included the 
demographic details of the patients, their date of 
admission and discharge, vital signs, serum 
creatinine, abnormal laboratory results, chief 
complaint, final diagnosis, comorbidities, pre-
admission medications, discharge medications, 
history of hospitalizations, past medical history. 
The details of their past medications were 
retrieved from the patients’ record and by directly 
asking them, or their caregivers, if further related 
information was required. All patient’s 
medications were considered in the study; 
including prescribed, over the counter, topical 
and inhaled medications. The comorbidities were 
scored using the age-combined Charlson 
Comorbidity Index (CCI) [25]. The patients’ 
activities of daily living (ADL) were assessed by 
the Katz scale [26] to identify disabled patients. 
The score of Katz scale ranges from 0 (totally 
independent patient) to 6 (highly dependent 
patient). The creatinine clearance was calculated 
using the Cockcroft Gault formula [27] for non-
obese patients and the Salazar Corcoran formula 
[28] for obese patients (patients with body mass 
index ≥ 30).  
 
Potentially inappropriate prescribing and 
polypharmacy 
 
The pre-admission and discharge medications of 
the patients were reviewed twice by the 
pharmacist in the study to identify the PIMs and 
PPOs using version 2 of the STOPP/START 
criteria. Polypharmacy is defined as taking five or 




The data were analysed using the Statistical 
Package for the Social Sciences version 24.0 
(IBM SPSS Statistics 24). The prevalence of 
PIMs (or PPOs) was defined as the percentile 
portion of patients who had at least one PIM (or 
PPO). Shapiro–Wilk normality test was 
performed to test the normality of continuous 
variables, and to subsequently select the 
statistical tests. McNemar’s test was used to 
assess the effect of hospitalization on the 
prevalence of PIMs and PPOs at pre- and post-
hospitalization. Wilcoxon signed-rank test was 
used to detect differences between the number 
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of medications, PIMs, and PPOs on admission 
and discharge. A multivariate logistic regression 
was employed to predict the risk factors for 
having PIM or PPO at the time of discharge. The 
variables included in the logistic regression 
model were age, sex, history of falls during the 
past three months, history of hospitalization 
during the last year, duration of hospitalization, 
age-combined CCI, number of discharge 
medications, and ADL status, which was treated 
as a dichotomous variable (either independent in 
all Katz scale aspects or dependent in at least 





Characteristics of the study population 
 
Of the 300 participants, 133 (44 %) were 
females. The mean ± SD age was 72 ± 6 years. 
The sample involved the three main ethnic 
groups in Malaysia, namely, Malays, Chinese, 
and Indians. Table 1 gives the details about the 
characteristics of the study population. One 
hundred and twenty-eight (42.6 %) patients had 
an age-combined CCI score of 5 or more, and  
 
Table 1: Characteristics of the study population (N = 
300 patients) 
 








Mean (SD) years 













Length of hospital stay 
Mean (SD) days 
Median (Range, IQR) days 
 
5.4 (3.7) 





Chronic kidney disease 
















Experienced falls in the past three 
months 
52 (17.3) 
Hospitalized in the last year 183 (61) 
* Except where otherwise indicated; ADL activities of 
daily living; CCI Charlson comorbidity index; SD 
standard deviation; IQR interquartile range 
107 were dependent in at least one ADL. The 
most encountered comorbidities were 
hypertension, followed by diabetes mellitus. 
 
Prescribed medications and polyphar-
macy 
 
Table 2 shows the number of prescribed 
medications and PIPs on admission and 
discharge. Patients were prescribed a mean ± 
SD of 5.5 ± 2.4 and 5.7 ± 2.5 medications on 
admission and discharge, respectively; which 
showed no significant difference (p = 0.99; 
Wilcoxon signed-ranks test). Polypharmacy was 
seen in 198 (66 %) and 199 (66.3 %) patients at 
pre- and post-hospitalization, respectively (p = 
0.99; McNemar’s test). The number of 
medications decreased in 75 patients, while it 
increased in 105 patients. 
 
Potentially inappropriate medications (PIMs) 
at pre- and post-hospitalization 
 
On admission, 27 % (81 patients; 97 PIMs) of the 
patients were on at least one PIM. Of these 
patients, 4 patients were on 3 PIMs (Table 2). 
Eighteen (22.5 %) out of the 80 STOPP criteria 
were represented on admission and/or 
discharge. 
 
The three most common PIMs on admission and 
discharge were vasodilators, that increase the 
risk of falls, and that were used on patients with 
persistent postural hypotension (31 and 28 
patients pre- and post-hospitalization, respect-
tively); metformin, that was used on patients with 
ClCr < 30 mL/min (13; 10 patients); and β-
blockers, that were used on patients with 
frequent hypoglycemic episodes (10; 10 patients) 
(Table 3). 
 
On discharge, the prevalence of PIMs was 
reduced to 22.3 % (67 patients; 85 PIMs; p = 
0.014; McNemar’s test). All the PIMs were 
stopped in 21 patients; however, 7 patients were 
introduced to new PIMs, while they were not on 
any PIM on admission (Table 4).  
 
There was no significant difference in the number 
of PIMs per patient before and after 
hospitalization (p = 0.06; Wilcoxon signed-ranks 
test). Moreover, none of the individual STOPP 
criteria significantly changed after discharge, 
meaning that there was no change in the pattern 
of PIM prescribing pre- and post-hospitalization 
(McNemar’s test) (Table 3). The applied logistic 
regression model to test the predictors of having 
PIM at discharge was statistically significant, 
where χ2 = 15.59, p = 0.04. It revealed that the 
absolute number of medications at discharge 
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Median (Rang, IQR) 
1-4 medications 
5-9 medications 


























































*Except where otherwise indicated; SD standard deviation; IQR interquartile range 
 
Table 3: Potentially Inappropriate Medications PIMs identified by the STOPP criteria, N=300 
 




Drug Indication Criteria 












“Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has 
a coronary stent(s) inserted in the previous 12 months or concurrent acute 





“Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or 
factor Xa inhibitors in patients with chronic atrial fibrillation” 
1 (0.3) 0 
Ticlopidine in any circumstances 7 (2.3) 7 (2.3) 
Central Nervous System and Psychotropic Drugs   
“Benzodiazepines for ≥ 4 weeks” 1 (0.3) 0 
“First-generation antihistamines” 1 (0.3) 1 (0.3) 
Renal System   
“NSAID’s if eGFR < 50 ml/min/1.73m2”   1 (0.3) 0 
 “Metformin if eGFR < 30 ml/min/1.73m2” 13 (4.3) 10 (3.3) 
Gastrointestinal System 
“Drugs likely to cause constipation in patients with chronic constipation where 




1 (0.3)  
Respiratory System   
“Systemic corticosteroids instead of inhaled corticosteroids for maintenance 
therapy in moderate-severe COPD” 
1 (0.3) 0 
“Anti-muscarinic bronchodilators with a history of narrow angle glaucoma or 
bladder outflow” 
3 (1) 2 (0.7) 
Musculoskeletal System   
“NSAID with severe hypertension” 1 (0.3) 0 
“Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where 
there is no contraindication to a xanthine-oxidase inhibitor” 
3 (1) 2 (0.7) 
Endocrine System   
“Sulphonylureas with a long duration of action with type 2 diabetes mellitus” 2 (0.7) 1 (0.3) 
“Beta-blockers in diabetes mellitus with frequent hypoglycemic episodes” 10 (3.3) 10 (3.3) 
Drugs that predictably increase the risk of falls in older people   
“Vasodilator drugs with persistent postural hypotension” 31* (10.3) 28** (9.3) 
Analgesic Drugs   
“Use of regular opioids without concomitant laxative” 0 3 (1) 
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Table 4: Changes in PIM at pre- and post-hospitalization 
 
Having at least 
one PIM on 
admission 
Discharged 










no change in 





81 (27 %) 21 (7.67 %) 3 (1 %) 6 (4.2 %) 50 (16.67 %) 7 (2.3 %) 
PIM potentially inappropriate medication 
 
Table 5: Potentially prescribing omissions (PPOs) identified by START criteria (N = 300) 
 




Cardiovascular system   
“Antiplatelet therapy with a documented history of coronary, cerebral or 
peripheral vascular disease” 
13 (4.3) 11 (3.7) 
“Statin therapy with a documented history of coronary, cerebral or 
peripheral vascular disease” 
10 (3.3) 12 (4) 
“Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure 
and/or documented coronary artery disease” 
33 (11) 33 (11) 
“Beta-blocker with ischemic heart disease” 25 (8.3) 24 (8) 
“Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) 
with stable systolic heart failure” 
5 (1.7) 6 (2) 
Respiratory system   
“Regular inhaled ß2 agonist or antimuscarinic bronchodilator mild to 
moderate asthma or COPD” 
18 (6) 16 (5.3) 
“Regular inhaled corticosteroid for moderate-severe asthma or COPD” 16 (5.3) 11 (3.7) 
Musculoskeletal system   
“Vitamin D supplement in older people who are housebound or 
experiencing falls or with osteopenia” 
40 (13.3) 40 (13.3) 
“Xanthine-oxidase inhibitors with a history of recurrent episodes of gout” 3 (1) 2 (0.6) 
Endocrine system   
“ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE 
inhibitor) in diabetes with evidence of renal disease” 
19 (6.3) 20 (6.7) 
Urogenital system   
“Alpha-1 receptor blocker with symptomatic prostatism, where 
prostatectomy is not considered necessary” 
10 (3.3) 10 (3.3) 
“5-alpha reductase inhibitor with symptomatic prostatism, where 
prostatectomy is not considered necessary” 
13 (4.3) 13 (4.3) 
COPD: chronic obstructive pulmonary disease 
 
(OR: 1.17, 95 % CI 1.038-1.32) and a previous 
experience of falls (OR 2.33, 95 % CI 1.19–
4.56)were significantly associated with the 
increased possibility of having PIM at discharge. 
The most common encountered PIMs in patients 
with history of falls were using vasodilators that 
increase the risk of falls followed by using two 
medications from the same drug class (duplicate 
drug class prescription). 
 
Potentially prescribing omissions (ppos) 
at pre- and post-hospitalization 
 
One hundred and forty-three patients (47.6 %) 
admitted to the hospital were having at least one 
PPO, with a total of 207 PPOs. One patient 
presented with 5 PPOs. The prevalence 
increased on discharge to 48 % (144 patients, 
201 PPOs; p = 0.99, McNemar’s test), with also 
one patient discharged with 5 PPOs (different 
from the one on admission) (Table 2). Out of the 
34 START criteria, 12 (35 %) were encountered 
on admission and discharge. The most 
commonly found PPO categories in descending 
order of frequency were PPOs pertaining to the 
cardiovascular system, musculoskeletal system, 
and respiratory system (Table 5). No significant 
changes were found either in the number of 
PPOs (p = 0.5; Wilcoxon signed-rank test) or in 
the individual START criteria on discharge 
(McNemar’s test) (Table 5). Hospitalization 
corrected all the PPOs in 11 patients. However, 
new PPOs were identified on discharge in 12 
patients, who did not have any PPO on 
admission. The applied logistic regression model 
to test the predictors of having PIM at discharge 
was statistically significant, where χ2 = 53.36, p < 
0.001. It revealed that a previous experience of 
falls (OR 10, 95 % CI 4.26–22.28), and age-
combined CCI (OR 1.21, 95 % CI 1.01–1.44) 
were significantly associated with having PPOs 
on discharge. The most frequently reported 
PPOs in patients with history of falls were the 
omission in vitamin D supplement, the omission 
of angiotensin-converting enzyme (ACE) inhibitor 
in diabetic patients with renal failure, and the 
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This study reported the influence of 
hospitalization on the prevalence of 
polypharmacy and PIPs, as defined by the 
STOPP/START criteria, among hospitalized 
community-dwelling elderly patients. The study 
revealed a significant decrease in the prevalence 
of PIMs coupled with an insignificant increase in 
the prevalence of PPOs. The study also found no 
changes in terms of the number of prescribed 
medications or polypharmacy at pre- and post-
hospitalization.  
 
A limited number of studies have been 
conducted to compare the prevalence of PIPs on 
admission and discharge, and their results were 
contradictory due to variations in terms of the 
study design, the detection tool used, hospital 
settings, and the characteristics of the study 
population. 
 
Wickop et al [22] reported an insignificant change 
in the prevalence of PIMs using three different 
explicit criteria - including the STOPP criteria - in 
a teaching hospital in Germany. Another study 
from Australia by Poudel et al [23] involving 
patients above 70 years old, who were admitted 
to a hospital from community-dwelling or long-
term care facilities, also showed an insignificant 
reduction in PIMs on discharge using Beers 
Criteria.  
 
A Norwegian study by Bakken et al [30] found a 
significant increase in PIMs, according to the 
NORGEP criteria, amongst community-dwelling 
people aged  70 years, who were admitted to 
internal medicine and orthopaedic surgery wards. 
In contrast, Onatade et al reported a significant 
reduction in PIMs in the Specialist Health and 
Ageing Unit in the UK using the STOPP criteria 
[20]. Compared with the number of studies that 
addressed this issue in western countries, little is 
known about this in the Asian region. Chen et al 
[31]  Investigated the prevalence of PIMs at 
discharge amongst inpatients admitted to the 
medical wards of a Taiwanese hospital using 
STOPP criteria. The study revealed a prevalence 
rate of 36.2 %. However, the authors reported no 
data about the prevalence of PIMs prior to 
admission. Morimoto et al [32] conducted a study 
in three Japanese hospitals, where they found a 
prevalence of 56.1 % of PIMs on admission 
according to the Beers Criteria.  
 
This study used the latest version (version 2) of 
STOPP/START criteria, in which some of the old 
criteria had been deleted and new ones added. 
However, most of the available published studies 
used version 1 of the criteria and this may further 
explain the differences between the results of 
this study and the results found in other studies. 
One of the most encountered STOPP categories 
on admission and discharge was “using drugs 
that predictably increase the risk of falls in older 
people”, which was also reported as one of the 
top classes of PIMs used in other studies 
[3,17,20,21,31], yet the types of drugs may have 
been different. The prescribing of these kinds of 
drugs to elderly patients is of concern since it is 
associated with falls and fracture-related 
hospitalizations [4]. The newly-added PIMs were 
quite common in the study population, which may 
indicate the importance of the recent updating of 
the STOPP criteria. PIMs pertaining to renal 
function and antiplatelet/anticoagulant drugs 
were both the second highest common STOPP 
categories. 
 
The use of benzodiazepines -in patients at risk of 
falls- was reported as a common PIM in several 
studies [17,21,35,36], whereas it was not 
encountered in the present study. This may be 
due to the low use of benzodiazepines in older 
patients in Malaysia, which was also reported by 
other researchers from a nursing home in 
Malaysia [37]. Other common PIMs that were 
reported in several studies [3,18,20,34], 
according to the STOPP criteria, were “aspirin 
with no history of coronary, cerebral or peripheral 
arterial occlusive symptoms” and “long-term 
opioids in patients with falls”. However, these 
criteria were removed from version 2 of the 
STOPP/START criteria.  
 
The significant decrease in the prevalence of 
PIMs at discharge may reflect an overall 
tendency of practitioners in the current hospital 
toward correcting pre-admission medications. On 
the other hand, failure to change any of the 
individual STOPP criteria for pre- and post-
hospitalization could be attributed partially to a 
lack of knowledge on the part of HCPs about the 
special criteria for prescribing for elderly patients. 
It is worth noting here that only 14 out of the 80 
STOPP criteria were found at discharge in the 
current study, which was fewer than that reported 
in other studies [20,21]. This shows that the 
inappropriate prescribing was concentrated in 
limited classes of medications, and the 
prescribing may be improved by boosting the 
knowledge of HCPs about these classes of 
medications. 
 
In the current study, the prevalence of PPOs on 
admission (47.6 %) was lower than the average 
rate reported in six different European countries 
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[17] (59.4 %), and higher than that observed in 
South Korea [38]. However, the prevalence of 
PPOs on discharge (48 %) was consistent with 
that of a study in Taiwan [31]. The insignificant 
impact of hospitalization on PPOs, as observed 
in this study, resembled that found by Manias et 
al [18], who reported a prevalence rate for PPOs 
of 60  and 63 % on admission and discharge, 
respectively. On the contrary, the results of the 
current study differed from those obtained in a 
study by Frankenthal et al, where there was a 
significant reduction in the prevalence of PPOs 
from 41 % on admission to 28.3 % on discharge 
[21]. 
 
The most common PPO identified in the current 
study was the omission of vitamin D supplements 
in patients with a history of falls (13 % pre- and 
post-hospitalization), which was newly-added to 
version 2 of the STOPP/START criteria. Anyway, 
the omission of vitamin D and calcium 
supplements was also common in other studies, 
but in patients with another coexisting risk factor, 
namely osteoporosis [17,21]. The omission of 
musculoskeletal medications is similar to 
prescribing medications predicting falls, it is 
associated with fall and fracture-related 
hospitalizations [4].  
 
The second most common PPO was the 
omission of ACE inhibitor (11 % pre- and post-
hospitalization) in patients with documented 
coronary artery diseases (CAD), which was a 
common PPO in previous studies [31,39]. The 
third most common PPO was the omission of ß-
adrenergic blocker in patients with documented 
CAD (8.3 and 8 % pre- and post-hospitalization), 
although this omission was not one of the top 
prevalent PPOs in other studies. Urogenital 
System PPOs, a new category under the START 
criteria, were also relatively common in the 
current study (7.6 % pre- and post-
hospitalization), where the -1 receptor blocker 
and 5- reductase inhibitor were omitted in 
patients with symptomatic prostatism. Other 
frequently reported START criteria in the 
literature [17,21,31], such as the “omission of 
aspirin or statin for the primary prevention of 
cardiovascular disease in diabetes mellitus”, 
were removed from version 2 of the START 
criteria. 
 
The current study showed that each additional 
medication prescribed at discharge increases the 
probability of having PIM by 1.2 times. It is 
obviously foreseeable that increasing the number 
of medications is associated with increasing the 
possibility for one of them to be inappropriate, 
and this is confirmed by other studies [17,20]. A 
high comorbidity index (age-combined CCI) 
score and history of falls are predictors of having 
PPOs at discharge. It is normal that having more 
diseases require more medications, where some 
of them may be inappropriately omitted, and this 
is consistent with the findings of other studies 
[17,40]. Additionally, it is not surprising that a 
recent experience of a fall is a predictor of having 
PIM and PPO, since the most prevalent PIM and 
PPO in the current study population were related 
to having a risk or history of falls. 
 
Strengths and limitations of the study 
 
This study had some limitations. It was 
conducted in one hospital only, and since there 
were no other similar studies in Malaysia to 
compare it with, it could not be assumed that the 
findings represent the practice in all Malaysian 
hospitals. Additionally, some information that was 
required to apply the criteria could not be 
retrieved, and that may have resulted in an 
underestimation of the prevalence of PIPs. For 
instance, no record was found pertaining to 
pneumonia or influenza vaccinations, which were 
required as part of the START criteria. On the 
other hand, we believe that this is the first study 
in Malaysia to have applied the STOPP/START 
criteria for hospitalized elderly patients and to 





The findings of this study indicate that 
hospitalization reduces the prevalence of pre-
admission PIMs among community-dwelling 
elderly patients. However, it did not influence the 
prevalence of PPOs or polypharmacy among this 
population. The most prevalent PIM at pre- and 
post-hospitalization is the prescribing of 
medications that increase the risk of falls in 
elderly patients and the most encountered PPO 
is the omission of vitamin D supplements in 
patients with a history of falls. The newly-added 
criteria of version 2 of the STOPP/START criteria 
are not uncommon in the study population. 
Having a history of fall or increasing the number 
of medications on discharge was associated with 
increasing the likelihood of having PIM, whilst 
having a high comorbidity index score or history 
of falls was a predictor of having PPO at 
discharge. Further studies in other Malaysian 
acute healthcare settings are required, and 
investigating the impact of educational 
interventions on the prescribing practices of 
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